July 26th 2024
The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Adjuvant Pembrolizumab Significantly Improved DMFS Vs Placebo in Resected Stage IIB/C Melanoma
March 8th 2022The phase KEYNOTE-716 trial, which assessed the use of adjuvant pembrolizumab in patients with resected stage IIB and IIC melanoma, met its secondary end point of distant metastasis-free survival.
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
Nivolumab/Ipilimumab +/- Dabrafenib and Trametinib Improved Survival for BRAF+ Metastatic Melanoma
November 17th 2021Phase 3 data indicated that the combination of nivolumab and ipilimumab followed by treatment with dabrafenib and trametinib, if necessary, resulted in greater overall survival at 2 years for patients with treatment-naïve BRAF-mutant metastatic melanoma.
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16th 2021Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
Future Promise for Advanced Melanoma Seen With Lifileucel TIL Therapy
November 4th 2021Lifileucel, a tumor infiltrating therapy, could be the best treatment for heavily pretreated patients with advanced melanoma, with investigators at Atlantic Health System examining this treatment modality in clinical trials.
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma
This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
FDA Accepts Biologics License Application for Tebentafusp in Metastatic Uveal Melanoma
August 25th 2021Tebentafusp has demonstrated promising responses in metastatic uveal melanoma, leading to FDA and European Medicines Agency approval of a biologics license application and marketing authorization application for the agent.